Welcome to our dedicated page for SciSparc Ltd. Ordinary Shares news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc Ltd. Ordinary Shares stock.
SciSparc Ltd. (Nasdaq: SPRC) is a specialty clinical-stage pharmaceutical company dedicated to developing innovative therapies for disorders of the central nervous system. With a strong focus on cannabinoid pharmaceuticals, the company is engaged in pioneering drug development programs targeting conditions like Tourette Syndrome, Alzheimer's disease, pain, Autism Spectrum Disorder (ASD), and status epilepticus using both THC and non-psychoactive CBD.
The company's robust pipeline includes SCI-110 for treating Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain management, and SCI-210 for ASD and status epilepticus. Recently, SciSparc enrolled the first patient in its clinical trial for SCI-210, aimed at treating children with ASD.
In addition to drug development, SciSparc owns a subsidiary focused on online sales of hemp-based wellness products, including gummies, oils, capsules, and creams.
SciSparc's commitment to scientific excellence is highlighted by its collaborations and partnerships. For example, its venture with MitoCareX Bio leverages advanced computational platforms for cancer drug discovery, targeting mitochondrial SLC25 proteins.
The company is also actively expanding its intellectual property portfolio, with recent patents granted in the U.S., Canada, and Europe. These patents cover innovative compositions that enhance the therapeutic effects of cannabinoids while reducing side effects, thereby boosting its competitive edge globally.
Latest News:
- March 8, 2024: First patient enrolled in ASD clinical trial for SCI-210.
- March 12, 2024: MitoCareX Bio screens millions of small molecules for potential anti-cancer treatments.
- March 14, 2024: First patient dosed in SCI-210 ASD trial.
- March 18, 2024: Granted Canadian patent for cannabinoid and n-acylethanolamine compositions.
- March 27, 2024: Clearmind partnership leads to multiple new patent applications.
- May 31, 2024: European Patent Office grants patent for antimicrobial compositions.
SciSparc Ltd. (Nasdaq: SPRC) announced the filing of an additional provisional patent application by Clearmind Medicine, focusing on the combination of Clearmind's MEAI and SciSparc's PEA for treating depression. This is part of a collaboration that has already seen three other patent applications filed for MEAI and PEA combinations targeting alcohol use disorder, cocaine addiction, and obesity. Furthermore, six more patents have been filed concerning PEA combined with various psychedelics including LSD and DMT. SciSparc aims to develop therapies for central nervous system disorders, with ongoing programs targeting Tourette Syndrome, Alzheimer's, pain, and autism spectrum disorder (ASD). With a focus on cannabinoid pharmaceuticals, the company is strategically positioned in the emerging psychedelic therapeutic market.
FAQ
What is the current stock price of SciSparc Ltd. Ordinary Shares (SPRC)?
What is the market cap of SciSparc Ltd. Ordinary Shares (SPRC)?
What does SciSparc Ltd. do?
What are SciSparc's main drug development programs?
What recent achievements has SciSparc announced?
What products does SciSparc offer online?
Where is SciSparc Ltd. based?
Is SciSparc involved in cancer research?
What patents has SciSparc recently secured?
Who leads SciSparc Ltd.?
What is SCI-210?
What is the significance of SciSparc's new patents?
